Concepedia

Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients

Tong Shen, Douglas E. James, Kathryn A. Krueger

Pharmaceutical Research · 2016 · 11 citations · 19 references

DOI

Concepts

References

19

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Jennifer G. Robinson, Michel Farnier, Michel Krempf et al. · New England Journal of Medicine · 2015 · 2.3K citations · Full text

, , +17

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 751 citations

, , +17

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice

Thomas A. Lagace, David E. Curtis, Rita Garuti et al. · Journal of Clinical Investigation · 2006 · 671 citations · Full text

, , +16

PCSK9: a convertase that coordinates LDL catabolism

Jay D. Horton, Jonathan C. Cohen, Helen H. Hobbs · Journal of Lipid Research · 2008 · 631 citations · Full text

, , +17

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Evan A. Stein, Dan Gipe, Jean Bergeron et al. · The Lancet · 2012 · 579 citations

, , +17